GSK grabs FDA OK for new shin­gles vac­cine, which will now tack­le a key Mer­ck fran­chise

Watch out Mer­ck. Glax­o­SmithK­line is com­ing for a chunk of your shin­gles vac­cine fran­chise.

Late on Fri­day the FDA an­nounced that it had green-light­ed Shin­grix, one of its biggest de­vel­op­ment pro­grams from the com­pa­ny’s vac­cines group. To­geth­er with the new COPD three-in-one com­bo Trel­e­gy El­lip­ta — ap­proved in Sep­tem­ber — and an HIV ther­a­py head­ed to a like­ly ap­proval, Shin­grix rep­re­sents one of GSK’s best shots at carv­ing our sig­nif­i­cant new rev­enue for it­self from new prod­ucts.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.